Home › Compare › BJGBF vs ABBV
BJGBF yields 38461.54% · ABBV yields 3.06%● Live data
📍 BJGBF pulled ahead of the other in Year 1
Combined, BJGBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BJGBF + ABBV for your $10,000?
Beijing Gas Blue Sky Holdings Limited, an investment holding company, engages in the sale and distribution of natural gas and other related products in the People's Republic of China. It operates through Natural Gas Refuelling Station; Trading and Distribution of Natural Gas; Direct Supply to Industrial Users; and City Gas, Pipeline Construction Fee, Value-Added Service and Others segments. The company operates compressed natural gas (CNG) and liquefied natural gas (LNG) refueling stations for vehicles; and distributes and trades in CNG, LNG fuel oil and other related oil by-products as a wholesaler to industrial and commercial users through direct supply facilities. It also sells natural gas to residential, industrial, and commercial users through pipelines. In addition, the company is involved in the provision of repair and maintenance, and pipeline construction. The company owns 29 gas refueling stations, including 17 CNG refueling stations and 12 LNG refueling stations. The company was formerly known as Blue Sky Power Holdings Limited and changed its name to Beijing Gas Blue Sky Holdings Limited in January 2017. Beijing Gas Blue Sky Holdings Limited was founded in 2000 and is headquartered in Central, Hong Kong.
Full BJGBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.